Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
BioPharma Dive
Fulcrum s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.
pharminent
June 2, 2026 (Last updated: June 3, 2026)
BioPharma Dive
Fulcrum s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.
